NCT02981615 is a Phase 3 clinical trial of Levofloxacin in Prevention, sponsored by Sheba Medical Center.

Who is sponsoring NCT02981615?

NCT02981615 is sponsored by Sheba Medical Center.

What drugs are being tested in NCT02981615?

Interventions in NCT02981615: Levofloxacin, Placebo Oral Tablet.

What condition does NCT02981615 study?

NCT02981615 studies Prevention.

Is NCT02981615 still recruiting?

NCT02981615 is currently completed. Last updated 27 November 2023.

Last reviewed 2023-11-27 · How we verify

NCT02981615

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients

Completed Phase 3 Last updated 27 November 2023

What this trial tests

Phase 3 trial testing Levofloxacin in Prevention in 67 participants. Completed in 30 July 2022.

Timeline

1 August 2017

Primary endpoint
30 July 2022

30 July 2022

Quick facts

Lead sponsor	Sheba Medical Center
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	67
Start date	1 August 2017
Primary completion	30 July 2022
Estimated completion	30 July 2022
Sites	1 location across Israel

Drugs / interventions tested

Levofloxacin (Levofloxacin) — full drug profile →
Placebo Oral Tablet — full drug profile →

Conditions studied

Prevention — all drugs for Prevention →

Sponsor

Sheba Medical Center

Who can join

18 and older, any sex, with Prevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Infections are a major and prevalent life-threatening complication among patients with myelodysplastic syndrome (MDS). Currently, the role of prophylactic antibacterial agents after chemotherapy in MDS patients remains controversial and there are no clinical guidelines for infection prophylaxis in this clinical setting. We will conduct a prospective study to evaluate the potential benefit of prophylactic antibacterial (Levofloxacin) on the rate of febrile episodes/infections in Azacytidine treated MDS patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?
Brunner AM, Fell G, Steensma DP. · · 2022 · cited 3× · PMID 35143613 · DOI 10.1182/bloodadvances.2021006357

Verify or expand the search:

Other trials of Levofloxacin

Trials testing the same drug.

NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
NCT07320534 — Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase · Phase 4 · not yet recruiting
NCT07198685 — 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province · NA · not yet recruiting
NCT07126639 — A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis · NA · not yet recruiting
NCT05743101 — Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke · NA · not yet recruiting

Other recruiting trials for Prevention

Currently open trials in the same condition.

NCT07511491 — Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section · NA · recruiting
NCT07248280 — Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatie · Phase 3 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07498530 — Virtual Assistant for Exercise Adherence in Older ADULTS · NA · recruiting
NCT06682494 — Enhancing Oral Cancer Awareness · NA · recruiting

Other Sheba Medical Center trials

Trials by the same sponsor.

NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
NCT07523373 — Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch · NA · not yet recruiting
NCT07509229 — 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients · Phase 1, PHASE2 · not yet recruiting
NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02981615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheba Medical Center
Last refreshed: 27 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02981615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing